US Patent Issued to BIOHENG THERAPEUTICS on Oct. 6 for "NKG2A-targeting antibody and use thereof" (Chinese Inventors)

ALEXANDRIA, Va., Oct. 6 -- United States Patent no. 12,753,231, issued on Oct. 6, was assigned to BIOHENG THERAPEUTICS Ltd. (Grand Cayman, Cayman Islands).

"NKG2A-targeting antibody and use thereof" was invented by Yali Zhou (Nanjing, China), Gong Chen (Nanjing, China), Xiaoyan Jiang (Nanjing, China), Tingting Guo (Nanjing, China), Jiangtao Ren (Nanjing, China), Xiaohong He (Nanjing, China), Yanbin Wang (Nanjing, China) and Lu Han (Nanjing, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are an NKG2A-targeting antibody, and a multispecific antibody, a chimeric receptor, an antibody conjugate, a pharmaceutical composition and a kit which comprise same, and the use thereof in the diagnosis/treatm...